The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases
Department of Clinical Immunology, Pathwest Laboratory Medicine, Queen Elizabeth II Medical Centre, Perth 6009, Western Australia, Australia
Department of Clinical Immunology, Royal Perth Hospital, Perth 6000, Western Australia, Australia
Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 08036, Spain
Victor Chang Cardiac Research Institute, Sydney, 2010, New South Wales, Australia
School of Medicine and Pharmacology, Anatomy, Physiology and Human Biology, CCTRM, University of Western Australia, Perth, 6009, Western Australia, Australia
School of Medicine and Pharmacology and School of Pathology and Laboratory Medicine, The University of Western Australia, Harry Perkins Institute of Medical Research, Perth, 6009, Western Australia, Australia
Institute for Immunology and Infectious Diseases, Murdoch University, Perth, 6150, Western Australia
Author to whom correspondence should be addressed.
Academic Editor: Jane Grant-Kels
Received: 31 March 2015 / Revised: 29 April 2015 / Accepted: 11 May 2015 / Published: 28 May 2015
The ability to generate inducible pluripotent stem cells (iPSCs) and the potential for their use in treatment of human disease is of immense interest. Autoimmune diseases, with their limited treatment choices are a potential target for the clinical application of stem cell and iPSC technology. IPSCs provide three potential ways of treating autoimmune disease; (i) providing pure replacement of lost cells (immuno-reconstitution); (ii) through immune-modulation of the disease process in vivo
; and (iii) for the purposes of disease modeling in vitro
. In this review, we will use examples of systemic, system-specific and organ-specific autoimmunity to explore the potential applications of iPSCs for treatment of autoimmune diseases and review the evidence of iPSC technology in auto-immunity to date.
This is an open access article distributed under the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Hew, M.; O'Connor, K.; Edel, M.J.; Lucas, M. The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases. J. Clin. Med. 2015, 4, 1193-1206.
Hew M, O'Connor K, Edel MJ, Lucas M. The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases. Journal of Clinical Medicine. 2015; 4(6):1193-1206.
Hew, Meilyn; O'Connor, Kevin; Edel, Michael J.; Lucas, Michaela. 2015. "The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases." J. Clin. Med. 4, no. 6: 1193-1206.
Show more citation formats
Show less citations formats
[Return to top]
For more information on the journal statistics, click here
Multiple requests from the same IP address are counted as one view.